

Endoscopic Suturing & Bariatric Endoscopy: The Next Frontiers in Endoluminal Surgery

Jonah Cohen, M.D.

Director of Bariatric Endoscopy
Center for Advanced Endoscopy
Beth Israel Deaconess Medical Center
Harvard Medical School

9.28.19



Beth Israel Deaconess
Medical Center



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Disclosure

No relevant conflicts of interest to disclose

Outline

- **A Brief History of Endoscopy**
- **Endoscopy Suturing & Overstitch**
- **Obesity in the U.S.**
- **Endoscopic Sleeve Gastroplasty**
- **Revisions and Fistulae**
- **Horizon Line**



Where We've Come From

FIRST ENDOSCOPE by Philip Bozzini 1806



Germany



Endoscopy in 2019



GIF-2TH180



Endoscopic Suturing



[ORBERA®](#)

[LAP-BAND®](#)

[OVERSTITCH™](#)

[NEWS](#)

[CONTACT US](#)


OverStitch™ endoscopic suturing system

**Creating a new market for
less invasive therapy.**




- Full-thickness
- FDA-approved for apposition of GI tract tissue
- Over 10,000 procedures performed: leaks, fistulae, RYGB stoma revision, EMR/ESD defects, POEM, ESG
- Disposable
- Therapeutic double-channel endoscope required

Endoscopic Suturing



Endoscopic Suturing



<https://www.youtube.com/watch?v=Q6FRT-cTdfU>

June 7, 2016, Vol 315, No. 21 >

[< Previous Article](#)

[Next Article >](#)

Original Investigation | June 7, 2016

Trends in Obesity Among Adults in the United States, 2005 to 2014

FREE

Katherine M. Flegal, PhD¹; Deanna Kruszon-Moran, MS¹; Margaret D. Carroll, MSPH¹; Cheryl D. Fryar, MSPH¹; Cynthia L. Ogden, PhD¹

Obesity: A Big U.S. Problem

- **Obesity ($BMI \geq 30$):**
 - **35% of men**
 - **40% of women**
- **Morbid obesity ($BMI >40$ or ≥ 35 with comorbidities)**
 - **5.5% for men**
 - **10% for women**
- **Economics: \$190 billion in 2005²**
- **21% of health care expenditures²**

1. Flegal, *JAMA*. 2016

2. Cawley J et al, *J Health Econ*. 2012



Obesity: Complications

- **Death** from all causes & from CVD
- **Disease:** DM2, HTN, HLD, gout, stroke, VTE, cholelithiasis, GERD, NAFLD, depression, OA, infertility, OSA, CAD, CHF, atrial fibrillation
- **Cancers:** breast, endometrial, cervical, liver, pancreatic, colon, gallbladder, kidney, leukemia
- **QOL:** negative social & economic consequences




Obesity: Unmet Needs Remain

- Despite advances in **neuronal, hormonal, metabolic & inflammatory** mechanisms of obesity, **bariatric surgery** remains **only current effective, long-term therapy**¹
- Only **1%** of qualified patients undergo surgery due to **limited access, patient preference, risks & costs**²




1. Sjostrom L. J Intern Med 2013

2. Mechanick JI, et al. Surgery for Obesity and Related Diseases 2013

Expanding Therapeutic Options



Endobariatric Armamentarium: 2018



Categories of Bariatric Endoscopy


Endoluminal Bariatric Procedures	Examples
1. Early-Intervention Procedures	Treating patients that are overweight or obese but who do not meet criteria for conventional bariatric surgery
2. Primary Obesity or Metabolic Procedures	Target is durable weight loss and/or focus on co-morbid metabolic conditions such as diabetes
3. Bridge Procedures	Offer short-term weight reduction to decrease operative risks associated with morbid obesity prior to bariatric surgery (i.e. IGBs)
4. Revisional Procedures	Addressing weight regain in traditional bariatric operations (i.e. TORe)
5. Post-Surgical Complication Procedures	Managing anastomotic leaks, stenosis, bleeding, strictures and fistulae
6. Endoscopy in Post-Surgical Patients	Includes procedures to access the pancreatobiliary limb in patients who have previously underwent bariatric surgery (i.e. single-balloon ERCP, EDGE)

Endoscopic Sleeve Gastroplasty


Surgical Gastric Sleeve
80% stomach removed to leave 'sleeve'





Endoscopic Sleeve Gastroplasty (ESG)
Stomach left intact, stitched to form 'sleeve'



BEFORE



AFTER



ESG Evidence: Durability

[Obes Surg.](#) 2017 Apr 27. doi: 10.1007/s11695-017-2693-7. [Epub ahead of print]

Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up.

[Lopez-Nava G](#)¹, [Sharaiha RZ](#)², [Vargas EJ](#)³, [Bazerbachi F](#)³, [Manoel GN](#)⁴, [Bautista-Castaño J](#)¹, [Acosta A](#)³, [Topazian MD](#)³, [Mundi MS](#)⁵, [Kumta N](#)², [Kahaleh M](#)², [Herr AM](#)², [Shukla A](#)², [Aronne L](#)⁶, [Gostout CJ](#)³, [Abu Dayyeh BK](#)⁷.

- 3 centers, retrospective
- 248 patients
- Age: 45 (mean), 73% female
- Baseline BMI: 38
- 6 months: %TBWL = 15.2%
- 24 months: %TBWL = 18.6%
- Five (2%) serious adverse events

ESG Evidence: Durability - 2019

Five-year ESG outcomes

Five-year ESG outcomes reveal significant total body weight loss



- The research showed less than 1 percent complications, an improvement over surgical procedures

- 15-20% TWL at 5 years

ESG Evidence: Metabolic

[Clin Gastroenterol Hepatol](#). 2017 Apr;15(4):504-510. doi: 10.1016/j.cgh.2016.12.012. Epub 2016 Dec 23.

Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients.

[Sharaiha RZ¹](#), [Kumta NA²](#), [Saumoy M²](#), [Desai AP²](#), [Sarkisian AM²](#), [Benevenuto A²](#), [Tyberg A²](#), [Kumar R³](#), [Igel L³](#), [Verna EC⁴](#), [Schwartz R²](#), [Frissora C²](#), [Shukla A³](#), [Aronne LJ³](#), [Kahaleh M²](#).

- Single center, prospective
- 91 patients
- Age: 44 (mean), 68% female
- Baseline BMI: 41
- 6 months: %TBWL = 14.4
- 12 months: %TBWL = 17.6
- 24 months: %TBWL = 20.9
- One (1%) serious adverse event (perigastric leak)

ESG Evidence: Metabolic

Clin Gastroenterol Hepatol. 2017 Apr;15(4):504-510. doi: 10.1016/j.cgh.2016.12.012. Epub 2016 Dec 23.

Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients.

Sharaiha RZ¹, Kumta NA², Saumoy M², Desai AP², Sarkisian AM², Benevenuto A², Tyberg A², Kumar R³, Igel L³, Verna EC⁴, Schwartz R², Frissora C², Shukla A³, Aronne LJ³, Kahaleh M².

Table 2. Post-ESG Improvement in Weight and Medical Comorbidities at 12 Months (N = 53)


	Before ESG, mean (SD)	12 months after ESG, mean (SD)	P value
HgbA1c, % (all patients)	6.1 (1.1)	5.5 (0.48)	.05
HgbA1c, % (only diabetes and prediabetes)	6.6 (1.2)	5.6 (0.51)	.02
Waist circumference, cm	119.66 (14.05)	92.75 (5.85)	<.001
SBP, mm Hg	129.02 (13.44)	122.23 (11.69)	.023
LDL, mg/dL	121.62 (38.61)	124.27 (27.82)	.786
TG, mg/dL	131.84 (83.19)	92.36 (39.43)	.017
ALT, mg/dL	32.28 (16.43)	20.68 (11.44)	<.001

Revisional Bariatric Endoscopy

- Trans-oral Outlet Reduction (TORe)
- Addressing weight regain after RYGB
- Etiologies of weight regain:
 - Nutritional habits
 - Psychosocial environment
 - Genetics
 - Fistula
 - Increased gastric pouch volume
 - Dilated gastrojejunal anastomosis (GJ)

Revisional Bariatric Endoscopy: TORe

- Outlet reduction:
 - Tissue ablation with APC
 - Interrupted or purse-string sutures at anastomotic margin
 - Goal reduction <1cm



TORe: 3 Year Data




Figure 2. Weight loss trend. *TORe*, transoral outlet reduction.

TABLE 2. Total weight loss with and without pouch reduction

	No pouch reduction	Pouch reduction	P value
12 mo	6.7 ± 1.5	9.9 ± 1.2	.10
24 mo	9.6 ± 2.4	6.5 ± 1.7	.28
36 mo	7.5 ± 2.3	7.2 ± 2.1	.94


Endoscopy for Post-Surgical Complications

- Anastomotic ulceration – GI bleeding
- Anastomotic stenosis
- **Gastro-gastric fistula**
- Surgical leaks
- Abdominal pain
- Sleeve stenosis
- Sleeve leaks
- Malnutrition in RYGB

Endoscopy for Post-Surgical Complications

- **GASTROGASTRIC FISTULA**

- Often presents with weight regain or marginal ulceration
- Endoscopic suturing closure carries decreased morbidity
- 20% successful closure at 12 months
- OTS Clips are an option but may interfere if surgery required



Other Applications of Endoscopic Suturing

- Suturing stents in place
- Managing iatrogenic perforations
- Closing POEM or G-POEM sites
- Closing large defects from EMR/ESD
- Gastro-cutaneous (i.e. PEG-related) fistula closure
- ? NOTES

Conclusion



Beth Israel Deaconess
Medical Center



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

Thank you

JMCOHEN@bidmc.harvard.edu

www.bidmc.org/CBE

